Generate Biomedicines, Inc. (GENB)
Healthcare
Biotechnology
14.00 $
-0.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Generate Biomedicines, Inc. (GENB) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -201 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2024 | 2025 |
|---|---|---|
| -118 | -201 | |
| 15 | 13 | |
| 19 | 21 | |
| 28 | -15 | |
| 3.4 | 3.5 | |
| -58 | 117 | |
| -11 | -8.2 | |
| 91 | 28 | |
| -84 | -56 | |
| -121 | -204 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.